中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2010年
2期
30-32
,共3页
Fas分子%肿瘤浸润淋巴细胞%外周血淋巴细胞%肺腺癌%免疫逃逸
Fas分子%腫瘤浸潤淋巴細胞%外週血淋巴細胞%肺腺癌%免疫逃逸
Fas분자%종류침윤림파세포%외주혈림파세포%폐선암%면역도일
Fas%Tumor infiltrating lymphocytes%Peripheral blood lymphocytes%Lung adenocarcinoma%Immune escape
目的 检测Fas分子在肺腺癌患者肿瘤浸润淋巴细胞(TILs)和外周血淋巴细胞(PBLs)中的表达,探讨Fas/FasL在肿瘤局部与全身免疫反应中的作用及临床意义.方法 用流式细胞术(FCM)对50例肺腺癌患者PBLs及TILs中Fas的表达进行定性定量分析,以48例正常人的PBLs为对照组.结果 Fas分子在肺腺癌患者TILs和PBLs中的表达率分别为16.8%和8.0%,对照组PBLs为12.6%,前者表达率明显高于后两者(P<0.05);而肺腺癌患者PBLs的Fas分子表达率明显低于对照组PBLs(P<0.05).结论 Fas分子在肺腺癌患者PBLs与TILs及其亚群中的表达不同,Fas/FasL在机体肿瘤局部及全身水平的免疫反应中起着重要作用.
目的 檢測Fas分子在肺腺癌患者腫瘤浸潤淋巴細胞(TILs)和外週血淋巴細胞(PBLs)中的錶達,探討Fas/FasL在腫瘤跼部與全身免疫反應中的作用及臨床意義.方法 用流式細胞術(FCM)對50例肺腺癌患者PBLs及TILs中Fas的錶達進行定性定量分析,以48例正常人的PBLs為對照組.結果 Fas分子在肺腺癌患者TILs和PBLs中的錶達率分彆為16.8%和8.0%,對照組PBLs為12.6%,前者錶達率明顯高于後兩者(P<0.05);而肺腺癌患者PBLs的Fas分子錶達率明顯低于對照組PBLs(P<0.05).結論 Fas分子在肺腺癌患者PBLs與TILs及其亞群中的錶達不同,Fas/FasL在機體腫瘤跼部及全身水平的免疫反應中起著重要作用.
목적 검측Fas분자재폐선암환자종류침윤림파세포(TILs)화외주혈림파세포(PBLs)중적표체,탐토Fas/FasL재종류국부여전신면역반응중적작용급림상의의.방법 용류식세포술(FCM)대50례폐선암환자PBLs급TILs중Fas적표체진행정성정량분석,이48례정상인적PBLs위대조조.결과 Fas분자재폐선암환자TILs화PBLs중적표체솔분별위16.8%화8.0%,대조조PBLs위12.6%,전자표체솔명현고우후량자(P<0.05);이폐선암환자PBLs적Fas분자표체솔명현저우대조조PBLs(P<0.05).결론 Fas분자재폐선암환자PBLs여TILs급기아군중적표체불동,Fas/FasL재궤체종류국부급전신수평적면역반응중기착중요작용.
Objective To study the Fas expression in tumor infiltrating lymphocytes (TILs)and peripheral blood lymphocytes(PBLs) from patients with pulmonary adenocarcinoma, and to investigate the clinical significance and the role of the Fas/FasL in local and systemic immune responses. Methods By flow cytometery(FCM),the expression of Fas molecule were detected on TILs and PBLs in 50 cases of lung adenocarcinoma and in 48 cases of normal healthy PBLs. Results Expression rate of Fas molecule on TILs and PBLs of lung adenocarcinoma patients was 16.8% and 8.0% respectively,and on PBL of normal controls was 12.6%. The former was significantly higher than the two latters(P<0.05). Expression rate of Fas molecule on PBLs of lung adenocarcinoma patients was significantly lower than the control group (P<0.05). Conclusions Expression of the Fas molecul on TILs and PBLs of lung adenocarcinoma patients is different. Fas/FasL pathway plays a major role in the fighting between immune system and tumor not only at local tumor site but also at systemic level.
